Nearly 20 years have passed since Memorial Sloan Kettering Cancer Center (MSK) first opened its doors in the Garden State. Since then, an explosion of knowledge and data has resulted in far better outcomes for thousands of people with cancer, including many who’ve sought care at MSK’s facility in New Jersey.
Monday, November 28, 2016
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.
Monday, October 31, 2016
When Memorial Sloan Kettering Cancer Center (MSK) opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive personalized cancer care. Today, more than 14 years later, MSK is reinforcing its commitment to the local community in the form of a 38,000-plus-square-foot addition complete with enhancements to both clinical programs and physical spaces.
Monday, October 17, 2016
See all press releases